DiBella N J, Brown G L
Cancer. 1978 Jul;42(1):149-58. doi: 10.1002/1097-0142(197807)42:1<149::aid-cncr2820420125>3.0.co;2-i.
Forty patients with various types of myeloproliferative disorders were evaluated immunologically. Serum immunoglobulin levels were within the normal range in most patients and no monoclonal gammopathies were detected. Serum C'3 levels were decreased in 19 of 40 (48%) patients. The response of peripheral blood lymphocytes to phytohemagglutinin was decreased in 26 of 40 (65%) and to pokeweed mitogen in 18 of 28 (64%) patients studied. Lymphocytes from patients with polycythemia vera were least affected. Unstimulated lymphocytes from some patients demonstrated markedly increased thymidine uptake activity. Despite the diminished mitogenic response, only 2 of 33 patients (6%) were anergic by intradermal skin testing. There was no association between depressed lymphocyte response and recent chemotherapy except in chronic myelogenous leukemia where 6 of 8 patients were receiving cytotoxic therapy when studied. These observations suggest that most of our patients with myeloproliferative disorders have abnormal cellular responses in vitro, but that delayed hypersensitivity and humoral responses are minimally affected.
对40例不同类型骨髓增殖性疾病患者进行了免疫学评估。大多数患者的血清免疫球蛋白水平在正常范围内，未检测到单克隆丙种球蛋白病。40例患者中有19例（48%）血清C'3水平降低。在研究的40例患者中有26例（65%）外周血淋巴细胞对植物血凝素的反应降低，28例患者中有18例（64%）对商陆有丝分裂原的反应降低。真性红细胞增多症患者的淋巴细胞受影响最小。一些患者未经刺激的淋巴细胞显示胸苷摄取活性明显增加。尽管有丝分裂原反应减弱，但33例患者中只有2例（6%）通过皮内皮肤试验显示无反应。淋巴细胞反应降低与近期化疗之间无关联，但慢性粒细胞白血病除外，在研究时8例患者中有6例正在接受细胞毒性治疗。这些观察结果表明，我们大多数骨髓增殖性疾病患者在体外有异常的细胞反应，但迟发型超敏反应和体液反应受影响最小。
